DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Average Rating of “Hold” from Brokerages

DiaSorin S.p.A. (OTCMKTS:DSRLF) has been given an average recommendation of “Hold” by the seven brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company.

Several research analysts have weighed in on the stock. Zacks Research upgraded shares of DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. BNP Paribas Exane downgraded shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 7th. UBS Group lowered DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Deutsche Bank Aktiengesellschaft cut DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. Finally, Piper Sandler began coverage on DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating for the company.

DiaSorin Stock Performance

Shares of DSRLF opened at $81.00 on Tuesday. DiaSorin has a 52-week low of $66.50 and a 52-week high of $100.00. The company has a 50-day simple moving average of $78.93 and a 200-day simple moving average of $76.58.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.